

03C0
PATENT #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrysek et al.

Attorney Docket No.: UD&LP049

Application No.: 09/642,242

Examiner: Unassigned

Filed: August 17, 2000

Group: Unassigned

Title: PHARMACEUTICAL COMPOSITIONS
FOR ORAL AND TOPICAL
ADMINISTRATION

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Assistant Commissioner for Patents, Washington, DC 20231 on October 30, 2000.

Signed: _____

Lara M. Nelson
Lara M. Nelson

TRANSMITTAL OF CERTIFIED PRIORITY DOCUMENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is the certified copy of the priority document for the above-referenced patent application, Great Britain Patent Application No. 9919288.2.

The Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0388 (Order No. UD&LP049).

Respectfully submitted,

BEYER WEAVER & THOMAS, LLP

Steve D Beyer

Registration No. 31,234

P.O. Box 778
Berkeley, CA 94704-0778

THIS PAGE BLANK (USPTO)



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

18 SEP 2000

THIS PAGE BLANK (USPTO)

For official use



17 AUG 1999

9919288.2

Your reference
RFB/P60175

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

2 Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning.

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The
Patent
Office

Request for grant of a Patent Form 1/77

Patents Act 1977

1 Title of invention

1 Please give the title of the invention

PHARMACEUTICAL COMPOSITIONS
FOR ORAL AND TOPICAL
ADMINISTRATION

2 Applicant's details

☐ First or only applicant

2a If you are applying as a corporate body please give:

Corporate name
GALENA AS

Country (and State of incorporation, if appropriate)
CZECH REPUBLIC

2b If you are applying as an individual or one of a partnership please give in full:

Surname
Forenames

2c In all cases, please give the following details:

Address
OSTRAVSKA 29
OPAVA 9
74770

UK postcode
(if applicable)

Country CZECH REPUBLIC
ADP number
(if known)

2d, 2e and 2f:

*If there are further applicants
please provide details on a separate
sheet of paper.*

☐ **Second applicant (if any)**

2d If you are applying as a corporate body please give:

Corporate name

Country (and State of incorporation, if appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f In all cases, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number
(if known)

3
An address for service in the United
Kingdom must be supplied.

Please mark correct box

3 Address for service details

3a Have you appointed an agent to deal with your application?

Yes ☒ No ☐ ➡ go to 3b



Please give details below

Agent's name

URQUHART-DYKES & LORD

Agent's address

TOWER HOUSE

MERRION WAY

LEEDS

WEST YORKSHIRE

Postcode LS2 8PA

Agent's ADP 1644004
number

3b:
*If you have appointed an agent,
all correspondence concerning
your application will be sent to
the agent's United Kingdom
address.*

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode
ADP number
(if known)

Daytime telephone
number(if available)

RFB/P60175

5 Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Please mark correct box

Yes ☐ No ☒ ➡ *go to 6*



please give details below

☐ number of earlier application or patent number

☐ filing date

```
{day month year}
```

☐ and the Section of the Patents Act 1977 under which you are claiming:

Please mark correct box

15(4) (Divisional) 8(3) 12(6) 37(4)

6

If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

6 Declaration of priority

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number (if known)	Filing date (day, month, year)
31		

7

The answer must be 'No' if:
- any applicant is not an inventor
- there is an inventor who is not an applicant, or
- any applicant is a corporate body.

8

Please supply duplicates of claim(s), abstract, description and drawing(s).

Please mark correct box(es)

9

You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here ➡

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark the correct box

Yes ☐ No ☒ ➡

A statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77

Claim(s)

3

Description

16

Abstract

1

Drawing(s)

2

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant (please state how many)

Patents Form 9/77 - Preliminary Examination/Search

Patents Form 10/77 - Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed 

Date 16/08/1999

(day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to:

☐ **The Comptroller
The Patent Office
Cardiff Road
NEWPORT
Gwent
NP9 1RH**

**The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY**

PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPICAL ADMINISTRATION

This invention relates to pharmaceutical formulations including, as the active ingredient, substances which are poorly soluble in water, for example therapeutically active cyclosporins, taxoides and taxanes.

Cyclosporins are a group of monocyclic, poly-N-methylated undecapeptides, which are naturally produced as secondary metabolites by certain fibrous fungi, especially of general *Tolypocladium* and *Cylindrocarpon*. Some therapeutically useful cyclosporin can be prepared by partial synthesis or by special fermentation procedures.

Cyclosporin (Cyclosporin A) is the first natural substance having selective immunosuppressive effect on lymphoid cells, especially T lymphocytes. It also influences functions of other cells of the immune system to a great extent.

Systemically administered cyclosporin is used therapeutically in organ transplantations or transplantations of bone-marrow. Cyclosporin can be employed for treating a wide variety of autoimmune diseases with inflammatory etiology and also as anti-parasitic agents.

Certain cyclosporins without immunosuppressive activity exhibit an inhibitor effect towards replication of the HIV-1 virus and can be employed in therapy for treatment and prevention of AIDS or AIDS related complex. The group of cyclosporins also include chemomodulators useful for influencing cross resistance of tumour cells to cytostatics.

Bioavailability of cyclosporin is influenced, on one hand, by specific properties of this group of substances, but also by the composition and properties of the particular dosage form. An important role in formulating therapeutic compositions containing cyclosporin is played by their high lipophilicity.

Solubility of these active substances in water typically does not exceed 2.5 mg/100 ml, which value is approximately 100 times lower than needed for regular absorption in the organism. The marked lipophilicity of cyclosporin is evidenced by the

values of their partition coefficients P in the system n -octanol/water. For cyclosporin, values of $\log P = 21.08$ to 2.99 have been reported.

To achieve acceptable bioavailability of cyclosporins formulations which are used in practice form dispersion systems and are characterised by the presence of a hydrophilic phase, a hydrophobic phase and a tensoactive component. The resulting dispersions are either classic emulsions or optically transparent microemulsions. Commercially available compositions for oral administration are known under the trade names Sandimunn®, Sandimunn®-Neoral, Consupren®, Implanta®, Imusporin® as described in GB 2015339, GB 2222770, GB 2270842 and GB 2278780.

Modifications of the preceding systems, where the hydrophilic base is omitted and replaced by partial esters of fatty acids with polyols like propylene glycol, glycerol or soritol, are described in GB 2228198.

German patent application DE 4322826 discloses, as the carrier system for drugs poorly soluble in water, a composition containing polyglyceryl esters of fatty acids as a co-tenside to non-ionic tensides having HLB higher than 10, in the presence of a triacyl glycerol as the lipophilic component.

Formulations containing cyclosporins in a vehicle comprising propylene glycol, mixed mono-, di- and triglyceride and a hydrophilic tenside, disclosed in GB 2248615, are typical microemulsion reconcentrates of the oil-in-water type.

According to biopharmaceutical classification, cyclosporins belong to class IV, ie substances whose solubility in water is bad and bioavailability is poor (G L Amidon, Biopharmaceutics Drug Classification and International Drug Regulation, Capsgel Library, Bornem 1996, p 15 - 30).

Taxoides are a group of natural substances isolated from some strains of *Taxus*. Taxoides demonstrate antineoplastic effects by influencing cellular mitosis. They are diterpenic substances containing taxanic cyclic grouping with a 4-membered oxitanic ring and an esteric side chain in position C_{13} . Natural paclitaxel and its semisynthetic derivative docetaxel are used for treatment of tumours. Taxanes are even less soluble in water than cyclosporins. Immediately after preparation, paclitaxel solubility in water ranges about $5 \mu\text{g/ml}$, however, paclitaxel hydrates which are formed on standing have an equilibrium concentration which is lower by an order of magnitude ($0.3 - 0.6 \mu\text{g/ml}$).

Compositions based on polyglycerol acylesters are known from the patent literature, eg PCT/GB97/02079. Pharmaceutical compositions for internal application containing cyclosporin as active ingredient and a carrier consisting of one or more partial esters of fatty acids with di- to decaglycerol and partial pentaglycerol to pentadecaglycerol acylesters are disclosed. Compositions prepared this way enable a skilled person to make a dispersion of emulsion type with an average particle size about 1 - 2 μm after dilution. The particles are of spherical character as shown in Figure 1. However, achievement of high bioavailability remains a problem.

Similarly, PCT/GB97/00131 discloses use of polyglycerol acylesters. Besides the above mentioned polyglycerolesters, the vehicle contains glycerol monoacylesters and optional substances selected from anhydrohexosdimethyl derivatives and/or polyethyleneglycerols. The formulation can also contain other substances which improve the stability of the vehicle and lipoaminoacids which are suitable especially for topical products. These compositions provide slightly dispersing systems containing spherical particles.

Other systems utilising polyglycerol esters with fatty acids are microemulsions. In EP-A-670715 or EP-A-334777, esters of fatty acids with polyglycerols are used for pharmaceutical or cosmetic microemulsions or compositions forming microemulsions. As defined in eg Lachman et al; Theory and Practice of Industrial Pharmacy, Lea & Febiger, Philadelphia 1970, p 463, a microemulsion is a clear dispersion of oil-in-water or water-in-oil having a size of dispersed particles in the range 100 - 600 Å. Dispersed particles in a microemulsion are composed of nanodrops or micellar aggregates of dispersed phase in dispersion medium. The shape of dispersed particles is mostly spherical.

Similarly, CZ-A-283516 describes use of polyglycerol acylesters as one of the components of vehicle which forms lyotropic liquid crystals in contact with an aqueous phase. In accordance with this specification and other patents (eg EP-A-314689 or EP-A-126751), only pharmaceutical compositions based on systems providing lyotropic liquid crystals are suitable and advantageous for formulations of biologically active substances which dissolve in the given system and/or have hydrophobic character. At the same time the capability of formation of a liquid crystal phase in vivo after application into the GI tract is associated with high bioavailability of hydrophobic pharmaceutical compositions.

According to a draft of the article Cyclosporine Modified Capsules for USP 23, published in Pharmaceopeial Forum Volume 24, Number 3, 1998, p 6155, high bioavailability of cyclosporin is conditioned by dispersion of a pharmaceutical composition in the form of a pre-concentrate after administration of a microemulsion into GI tract. The draft recommends to test whether the dispersion arising after dilution of such composition provides particles of mean size 50 nm in the dispersed phase. This topic is discussed in several patents which however do not disclose use of polyglycerol esters of higher fatty acids.

However, it has been surprisingly found out that high bioavailability of cyclosporins and taxanes after oral application can be achieved using a system neither based on liquid crystals nor a microemulsion. It was also found that a system prepared in accordance with the present invention does not result in a dispersion of the emulsion type.

Unexpectedly it has been found that particles which are formed spontaneously or almost spontaneously have a non-spherical character. At the same time, no sign of anisotropic grouping of molecules was found even if the particles formed exhibited a dramatic increase in viscosity. From these findings it appears that it is a dispersion of particles having gel-like properties in water.

In this specification particles of gel-like character are to be understood as those whose stable shape or conformation in the dispersion is non-spherical. Non-spherical particles are those having at least two different perpendicular dimensions.

In this specification a gel emulsion (GEM) is to be understood as a dispersion of particles of gel character in an aqueous phase.

In a pre-concentrate of gel emulsion (PRO-GEM) is to be understood as a composition which results in a gel emulsion after dilution or in contact with an aqueous phase.

The formation of gel particles is conditioned by interaction between a hydrophilic gelator (an agent which causes formation of gel) and a lipophilic gel-creating phase. Such a composition may contain components which participate in the formation of particulate gel structure and which facilitate spontaneous dispersion in an aqueous medium. It may also contain components which ensure oxidative or microbial stability, masking the taste,

● adjusting the appearance or to facilitate dissolution of active ingredients in the mixture.
The composition may also contain components which adjust viscosity.

Pharmaceutical compositions in accordance with the present invention may be used to formulate active substances from class IV according to the biopharmaceutical classification.

According to the present invention a pharmaceutical formulation for oral or topical administration comprises

- a) 0.1 to 30.0 % of one or more hydrophobic active ingredients;
- b) 0.1 to 60.0 % of one or more gelators comprising fatty acid esters of polyglycerol;
- c) 0.1 to 60.0 % of one or more gel-creating substances selected from esters of polyglycerol with fatty acids and/or unsaturated fatty alcohols;
- d) 1.0 to 60 % of one or more co-gelator substances selected from: macrogolglycerolester of fatty acids, macrogolglycerolester of vegetable oils, macrogolesters of fatty acids, mono- and di- macrogolesters of mono-, di- and tri-acylglycerols.

e) 5.0 to 30 % of one or more C_2 to C_4 alcohols;
wherein the above percentages are selected to total 100% and the ratio of a : c and/or a : e is in the range 0.001 : 1 to 10 : 1;

and wherein upon dilution with water the formulation forms a dispersion of polymorphous gel particles having a dimension of 0.2 to 500 μm .

Weights, percentages and amounts used in this specification are by weight unless indicated otherwise.

Pharmaceutical compositions in accordance with the present invention may be characterised in that after dilution by aqueous phase in ratio from approx 1 : 5 (composition : aqueous phase) to approx 1 : 100, a dispersion of gel particles in water with mean size of particles between 0.2 - 500 μm is obtained. Such dispersion may be referred to as a gel emulsion (GEM).

Gel emulsion pre-concentrates (PRO-GEM) may be administered in the form of a pre-concentrate or in single-dose dosage forms such as capsules.


Component a) includes biologically active ingredients, which are insufficiently soluble in water for conventional formulation and so their bioavailability is low. According to this biopharmaceutical classification, these are substances of group 2 and 4, with low water solubility. The substances belong into a group of immunosuppressives, antitumour chemotherapeutical agents, substances influencing saccharide metabolism, peptides and lipids, agents influencing the calcium channel, non-steroidal antiflogistics and vitamins.

Immunosuppressives are hydrophobic compositions and include N-methylated cyclic undecapeptides. Cyclosporins are preferably used, especially ciklosporin (also known as Ciklosporin or Cyklosporin A), [Nva]² - ciklosporin (cyklosporin G) and [Melle]⁴ - ciklosporin. Non-immunosuppressive cyclosporines can also be used, eg [3'ketoMBmt]¹-[Val]²-ciklosporin. Other immunosuppressives can be used too, eg macrolides produced by grampositive Streptomyces bacteria (rapamycine, tacrolimus) or their derivatives.

Antitumour chemotherapeutic agents include taxanes, preferably docetaxel or paclitaxel.

Other biologically active ingredients which may be formulated in accordance with this invention may be selected from: diclofenac, ibuprofen, nifedipine, triamcinolone, tocopherol etc. In accordance with the present invention, the compositions can contain as much as 30% of the active ingredient.

Component b) which may be considered as a gelator is selected from polyglycerol esters of fatty acids, of general formula (I)



where n is an integer from 4 - 13 and R = H or CO.R¹ wherein R¹ is C₈₋₂₂ saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen.

Preferred components b) are polyglycerol esters and partial esters of medium or long chain fatty acids. These preferably have a HLB value not less than 10.

Polyglycerol esters with fatty acids are generally prepared by either partial or full esterification of polyglycerols by corresponding fatty acids or trans-esterification of vegetable oils with polyglycerol. Each polyglycerol monoester may be characterised by a saponification number. The level of polymerization is best indicated by the hydroxyl number. Polyglycerol esters with HLB value greater than about 10 may be considered to be hydrophilic. Polyglycerol esters with a HLB value less than about 9 may be considered lipophilic. Substances suitable for the components b) include the following:


Name (INCI)	Number of glycerol units	HLB
Polyglycerol-60-monolaurate	6	14.5
Polyglyceryl-10-monolaurate	10	15.5
Polyglyceryl-10-monomyristate	10	14.0
Polyglyceryl-10-monostearate	10	12.0
Polyglyceryl-10-mono-dioleate	10	11.0
Polyglyceryl-10-diisostearate	10	10.0
Polyglyceryl-6-monomyristate	6	11.0
Polyglyceryl-8-monooleate	8	11.0
Polyglyceryl-10-monooleate	10	12.0

The above mentioned polyglycerols esters are available from Nikko Chemicals Co under the trade name NIKKOL®, Durkee Foods under the trade name SANTONE® or Abitec Corp under the trade name CAPROL®.

Polyglycerols esters of components b) and c) for use in the compositions of this invention preferably meet the following purity requirements:

acid no = max 6; heavy metals content = max 10 ppm; water content = max 2%; content of Na salts of fatty acids = max 2% (as Na stearate); total ash = max 1%.

Component c), which may be considered as a gel-creating substance, is selected from polyglycerol esters of fatty acids and/or unsaturated fatty alcohols, and is preferably of general formula (2)



wherein n is an integer from 0 - 10 and R = H or CO.R" wherein R" is C₈₋₂₂ saturated, unsaturated or hydroxylated alkyl, and wherein while at least one group R is not hydrogen.

Preferred components c) are polyglycerol esters and partial esters of fatty acids and/or fatty alcohols. Preferred components c) have a HLB value not greater than 9. Substances suitable for components c) include the following:

Name (INCI)	Number of glycerol units	HLB
Polyglyceryl-3-monooleate	3	6.5
Polyglyceryl-6-dioleate	6	8.5
Polyglyceryl-10-tetraoleate	10	6.2
Polyglyceryl-10-decaoleate	10	3.5
Polyglyceryl-2-monostearate	2	5.0
Polyglyceryl-10-pentastearate	10	3.5

The above mentioned polyglycerols esters are available from Nikko Chemicals Co under the name NIKKOL®; or Abitec Corp under the trade name CAPROL®.

Preferred components c) include gel-creating substances selected from polyglycerol esters of fatty acids and/or unsaturated fatty alcohols is in accordance with

the present invention a substance especially selected from C₈₋₂₂ unsaturated fatty alcohols. Preferably oleyl alcohol (9-octadecen-1 ol) can be used for example meeting the following purity requirements:

Mr = 268,49; refractive index = 1,458 - 1,460; acid no < 1; hydroxyl no = 205 - 215; iodine no = 85 - 95.

Component d), which may be considered to be a co-gelator, may be selected from: macrogolglycerolesters of fatty acids. These may be esters of C₈₋₂₂ fatty acids, unhydrogenated or hydrogenated with macrogol glycerols.

Especially preferred are macrogol glycerols with vegetable oils eg ricine oil, both hydrogenated and unhydrogenated, almond or maize oil. They are generally prepared by reaction of various quantities of ethyleneoxide and the appropriate type of oil under known conditions. Especially preferred are the following substances characterised by the number of reacted ethylene oxide mols (1 + m + n + x + y + z) and HLB value.

	(1+m+n+x+y+z)	HLB
macrogol(1540) ricine-oleic glyceride	35	12-14
macrogol(1760) hydrogenated ricine-oleic glyceride	40	12.5-16
macrogol(2200) hydrogenated ricine-oleic glyceride	50	13.5
macrogol(2640) hydrogenated ricine-oleic glyceride	60	14.5
macrogol(3520) hydrogenated ricine-oleic glyceride	80	15
macrogol(4400) hydrogenated ricine-oleic glyceride	100	16.5
macrogol(2640) almond-oleic glyceride	60	15
macrogol(2640) maize-oleic glyceride	60	15

Characteristic physical and chemical parameters of the above mentioned substances are:

acid no \leq 2; hydroxyl no = 40 - 60; iodine no $<$ 1*; saponification no = 40 - 70; water content $<$ 3%;
(*- for macrogol(1540) ricine-oleic glyceride = 28 - 32).

These substances are commercially available under the trade names eg Cremophor®, Nikkol®, Simulsol®, Mapeg®, Crovol®.

Special mixed mono- and d- macrogolesters of mono-, di- and triacylglycerol commercially available under the trade name Gelucire® are also preferred. Especially preferred products are available under the name Gelucire® 50/13 and 44/14. Preferred physicochemical properties are:

acid no $<$ 2,00; saponification no = 65 - 95; iodine no $<$ 2; hydroxyl no = 36 - 56; peroxide no $<$ 6; alkaline impurities $<$ 80 ppm; free glycerol $<$ 3,00 %.

Alternative compositions preferred for use as compound d) are macrogolesters of fatty acids eg macrogol(660)-12-hydroxystearate commercially available under the trade name Solutol® HS 15 having an acid no $<$ 1; water content $<$ 0.5%; saponification no = 53 - 63 and hydroxyl no = 90 - 110.

Component d) is usually present in the compositions in an amount of 1 - 60 %, preferably in the range 5 - 50 % and most preferably 15 - 50% and most preferably 15 - 40 %.

Component e) is selected from C₂ - C₄ alkanols, preferably ethyl alcohol of pharmaceopoeial quality. In topical applications, propan-2-ol, or 2-methyl-1-propanol, are preferred.

Other excipients which can be employed in compositions of the present invention are those which influence physicochemical and microbial stability (eg antioxidants, anti-microbial additives such as tocopherol, methyl paraben), organoleptic properties (eg taste correctors based on natural or nature identical aromas) or physical properties which may limit processing (eg viscosity or melting point). The following can be included among

● such substances: water or other pharmaceutically acceptable solvents, hydrophilic colloids eg selected from derivatives of cellulose, chitosans, alginate, polycarbophile etc.

Compositions based on a gel pre-concentrate may be characterised in that they disperse into particles of gel character primarily of irregular shape after application into an aqueous medium. High bioavailability of such compositions is associated with bioadhesion. As a result of their amphiphility, these particles are less liable to coalescence and may be homogenously dispersed in an aqueous medium. In contact with a lipophilic surface they remain on the surface and so provide a sufficient concentration gradient to enable drug penetration through the membrane due to their viscosity and adhesivity.

The invention is further described by means of example but not in any limitative sense with reference to the accompanying drawings of which:

Figure 1 is a photomicrograph of a dispersion in accordance with PCT/GB97/02079;

Figure 2 is a photomicrograph of a dispersion in accordance with the present invention; and

Figure 3 is a graph showing blood levels of cyclosporin in example 6.

Example 1

Cyclosporine-containing solution for oral or topical application:

The following ingredients were employed.

a)	cyclosporin A	3600 g
b)	polyglycerol-10-mono-dioleate	7200 g
c)	oleyl alcohol	7200 g
d)	macrogol(1760) hydrogenated ricine-oleic glyceride	14400 g
e)	ethanol	4000 g
f)	D- α -tocopherol	180 g

Composition a) was mixed with compositions e) and c). The whole mixture was then homogenized until the active ingredient was dissolved. Then, compositions b) and d) and any other auxiliary ingredients were added. After complete homogenization the

resulting solution was filtered through a hydrophobic membrane GVHP (Millipore) of porosity 0.2 - 5.0 μm into a gasproof vessel under an inert atmosphere. When required for use the filtered solution was packed under an inert atmosphere into 50 ml bottles equipped with gasproof stoppers.

Example 2

Hard gelatin capsules of size "Elongated 0"

The following ingredients were employed.

a)	cyclosporine A	50.0 mg
b)	polyglyceryl-10-monooleate	100.0 mg
c)	polyglyceryl-3-monooleate	15.0 mg
d)	macrogol(2640) hydrogenated ricine-oleic glyceride	140.0 mg
e)	ethanol	80.0 mg

The fill for hard gelatin capsules was prepared using working procedure identical to that of Example 1 and filled into hard gelatin capsules of size "EO".

Example 3

Soft gelatin capsules of size oblong 20:

The following ingredients were employed.

a)	cyclosporine A	100.0 mg
b)	polyglyceryl-6-monolaurate	120.0 mg
c)	polyglyceryl-10-tetraoleate	410.0 mg
d)	Gelucire 50/13	300.0 mg
e)	ethanol	170.0 mg

The fill for soft gelatin capsules was prepared by a procedure identical to that of Example 1. The fill was filtered into a 20 l stainless-steel vessel equipped with a gasproof stopper. The fill was kept in inert atmosphere between filtration and encapsulation.

- Encapsulation was carried out using a conventional procedure into standard type of gelatin mixture.

Example 4

Hard HPMC capsules (Shionogi Qualicaps) of size 3:

The following ingredients were employed.

a)	cyclosporin A	25.0 mg
b)	polyglyceryl-10-myristate	50.0 mg
c)	polyglyceryl-10-pentastearate	70.0 mg
d)	macrogol(2640) almond-oleic glyceride	75.0 mg
e)	ethanol	30.0 mg

Composition a) was mixed with compositions e) and b). The mixture was heated to 40 - 50°C and homogenised until composition a) was dissolved. Then, composition d) was added. Finally, composition c) was added. The mixture was continuously mixed. The temperature of the mixture did not exceed 60°C during preparation. After complete dissolution and homogenization of all ingredients the product is filtered through a pre-filter and filled into hard cellulose capsules (eg supplied by Syntapharm) of size 3.

Example 5

Visualisation of gel emulsion

Pre-concentrates in accordance with patent application PCT/GB97/02079, Example 1 and as disclosed in Example 1 of this invention were each diluted with water in ratio 1 : 20 (product : water) and dispersed on a laboratory shaker (IKA HS - B20) for 10 minutes at temperature $25 \pm 1^\circ\text{C}$. Pictures of the dispersed samples were taken by means of a COHU camera connected to an optical microscope. The pictures were evaluated by means of software LUCIA™ (Laboratory Imaging Inc). Photomicrography of a dispersion of the emulsion type in accordance with PCT/GB97/02079 is shown in Figure 1. Photomicrography of a dispersion of the type of gel emulsion arising from a pre-concentrate according to Example 1 of the present invention is represented by Figure 2.

Example 6

Verification of bioavailability of medicinal products on base of pre-concentrate of gel emulsion

The composition according to Example 1 was compared with the commercially available microemulsion product Neoral® oral solution. The composition according to Example 1 was given clinical code L363, Neoral® oral solution was tested under code L352.

Pharmacokinetics were compared after single-dose administration of 100 mg cyclosporine to five beagle dogs in a two-phase experiment. Males of 12 - 36 months of age and weight 9 - 15 kg were fed using a standard pellet diet in quantity 300 g per day with water ad libitum. The product was administered after 18 hour fasting. Blood samples were collected from the antebrachial vein in intervals of 0, 1, 2, 3, 5, 8, 12 and 24 hour. The blood samples were stabilized using complexone and kept in a refrigerator until analysis was performed by non-specific radioimmunoassay. Comparison of mean bioavailabilities represented by mean values of cyclosporin A blood concentration is shown in Figure 3. It is clear from the comparison that bioavailability of products based on a gel emulsion pre-concentrate which created a dispersion of non-spherical particles of mean size 0.2 - 500 μm after dilution with water, was comparable or higher than that of products forming microemulsion of average size of particles about 100 nm.

Example 7

Fills for soft gelatin capsules containing paclitaxel:

The following ingredients were employed.

a)	paclitaxel	78.75 mg
b)	polyglyceryl-10-mono-dioleate	205.00 mg
c)	polyglyceryl-3-monooleate	129.50 mg
c)	oleyl alcohol	205.00 mg
d)	macrogol(1760) hydrogenated ricine-oleic glyceride	302.00 mg
e)	ethanol	129.50 mg

● Example 8

Composition of soft gelatin capsules

The following ingredients were employed.

a)	paclitaxel	78.75 mg
a)	[3'ketoMBmt] ¹ -[Val] ² -cyclosporin	52.50 mg
b)	polyglyceryl-10-mono-dioleate	187.50 mg
c)	oleyl alcohol	187.50 mg
c)	polyglyceryl-3-monooleate	112.50 mg
d)	macrogol(1760) hydrogenated ricine-oleic glyceride	302.00 mg
e)	ethanol	129.50 mg

Example 9

Fill for soft gelatin capsules containing nifedipine

The following ingredients were employed.

a)	nifedipine	20.00 mg
b)	polyglyceryl-10-nono-dioleate	205.00 mg
c)	polyglyceryl-3-monooleate	129.50 mg
c)	oleyl alcohol	205.00 mg
d)	macrogol(1760) hydrogenated ricine-oleic glyceride	302.00 mg
e)	ethanol	129.50 mg

Examples 10 - 17

Table 1 gives further examples of preparations illustrating the invention. The method of preparation was identical to that of Example 1.

Table 1

Example No/Component	A	B	<u>C</u> ₁	<u>C</u> ₂	<u>D</u>	<u>E</u>
10	10.0	19.0	19.0	12.0	28.0	12.0
11	10.0	23.0	19.0	15.0	28.0	5.0
12	10.0	13.0	19.0	8.0	28.0	20.0
13	0.1	5.0	19.9	15.0	50.0	10.0
14	10.0	37.0	19.0	12.0	10.0	12.0
15	10.0	1.0	19.0	30.0	28.0	12.0
16	0.1	21.1	---	34.7	31.1	13.0
17	30.0	10.0	15.0	6.0	22.0	17/0

The following raw materials were used in Examples 10 - 17:


- A -cyclosporine A
- B -polyglyceryl-10-mono-dioleate
- C₁ -oleyl alcohol
- C₂ -polyglyceryl-3-monoleate
- D -macrogol(1760) hydrogenated ricine-oleic glyceride
- E -ethanol

CLAIMS

1. A pharmaceutical formulation for oral or topical administration including
 - a) 0.1 to 30.0 % of one or more hydrophobic active ingredients;
 - b) 0.1 to 60.0 % of one or more gelators comprising fatty acid esters of polyglycerol;
 - c) 0.1 to 60.0 % of one or more gel-creating substances selected from esters of polyglycerol with fatty acids and/or unsaturated fatty alcohols;
 - d) 1.0 to 60 % of one or more co-gelator substances selected from: macroglycerolester of fatty acids, macroglycerolester of vegetable oils, macroglycerolesters of fatty acids, mono- and di- macroglycerolesters of mono-, di- and tri-acylglycerols.
 - e) 5.0 to 30 % of one or more C₂ to C₄ alcohols;


wherein the above percentages are selected to total 100% and the ratio of a : c and/or a : e is in the range 0.001 : 1 to 10 : 1;

and wherein upon dilution with water the formulation forms a dispersion of polymorphous gel particles having a dimension of 0.2 to 500 μm.
2. A formulation as claimed in claim 1, wherein component b) is selected from polyglycerol esters of fatty acids of formula (1)



wherein n is an integer from 4 to 13 and R is H or CO.R' wherein R' is C₈₋₂₂ saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen.

3. A formulation as claimed in claim 1 or 2, wherein component c) is selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids of formula (2).



wherein n is an integer from 0 - 10 and R = H or CO.R'' wherein R'' is C₈₋₂₂ saturated, unsaturated or hydroxylated alkyl, and wherein while at least one group R is not hydrogen.

4. A formulation as claimed in any preceding claim, wherein component d) is selected from triglyceride macrogol glycerol esters, partial glycerides or fatty acids or macrogol esters of fatty acids in which the average quantity of reacted ethylene oxide in the synthesis of these substances ranges between 50 to 150 mols and concurrently the ratio between components b) and d) is from 0.1 : 1 to 10 : 1.

5. A formulation as claimed in any preceding claim, wherein the component a) is selected from cyclosporins especially cyclosporin A, cyclosporin D or cyclosporin G, wherein the ratio of components a : c + e is 1.001 : 1 to 1.5 : 1.

6. A formulation as claimed in any of claims 1 to 5, wherein component a) is selected from taxanes, especially docataxel or paclitaxel, wherein the ratio between components a : c + e is 0.001 : 1 to 1.5 : 1.

7. A formulation as claimed in any preceding claim, wherein component a) includes at least one substance selected from the group comprising cyclosporins and at least one substance selected from the group comprising taxanes.

8. A formulation as claimed in any preceding claim, further including excipients to modify the physical, chemical, microbial stability, organoleptic or physical processing properties of the formulation.

ABSTRACT

PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPICAL
ADMINISTRATION

A pharmaceutical formulation for oral or topical administration including


- a) 0.1 to 30.0 % of one or more hydrophobic active ingredients;
- b) 0.1 to 60.0 % of one or more hydrophilic fatty acid esters of glycerol;
- c) 0.1 to 60.0 % of one or more substances selected from lipophilic esters of polyglycerol with fatty acids and/or unsaturated fatty alcohols;
- d) 1.0 to 60 % of one or more substances selected from: triglyceride macrogolglycerol esters, partial fatty acid glycerides and partial fatty acid macrogol esters;
- e) 5.0 to 30 % of one or more C₂ to C₄ alcohols;

wherein the above percentages are selected to total 100% and the ratio of a : c and/or a : e is in the range 0.001 : 1 to 10 : 1;

and wherein upon dilution with water the formulation forms a dispersion of polymorphous gel particles having a dimension of 0.2 to 500 μm .


Figure 1:

o / v emulsion; continuous hydrophilic phase and lipophilic oily droplets




5 Figure 2:

o / v gel emulsion; continuous hydrophilic phase and dispersed non - spherical gel particles



THIS PAGE BLANK (USPTO)

Picture 3



THIS PAGE BLANK (USPTO)